EuropeResearch and clinical trials
Blood pressure drug irbesartan reduced vascular events over two years in vascular EDS
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
Irbesartan was tested in a trial with 57 adults with vascular EDS. All were already taking celiprolol. For two years, irbesartan was added in one group and an inactive drug in the other. Serious vascular events or new blood vessel damage occurred in 27.6% of the irbesartan group and 53.6% of the other group. Low blood pressure occurred 11 times.
What does it mean for patients and families?
This is one of the first controlled trials in this disease, but it is small. Do not change your medication on your own; make that decision with your doctor.
Source
Scientific paper: Efficacy of Irbesartan in Celiprolol-Treated Patients With Vascular Ehlers-Danlos Syndrome. Circulation, 2025. DOI: 10.1161/CIRCULATIONAHA.124.072849 · PubMed 39906986
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Vascular Ehlers-Danlos syndrome (vEDS)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.